TY - JOUR
T1 - Intracerebral haemorrhage
AU - Puy, Laurent
AU - Parry-Jones, Adrian R.
AU - Sandset, Else Charlotte
AU - Dowlatshahi, Dar
AU - Ziai, Wendy
AU - Cordonnier, Charlotte
N1 - Funding Information:
L.P. received speaker fees from Daichi–Sankyo. A.R.P.-J. participated in advisory boards for and received speaker’s fees from Alexion Pharmaceuticals, Inc. E.C.S. is on the steering committee of ANNEXAi. D.D. holds a patent for the CARL software to automatically detect contrast extravasation, has received honoraria from AstraZeneca Canada, is on the steering committee of the FASTEST and ENRICH-AF trials. W.Z. is supported by the NIH (1U01NS080824, R01NS102583, U01NS106513 and 1R01NS120557). C.C. received speaker fees from BMS and Pfizer.
Publisher Copyright:
© 2023, Springer Nature Limited.
PY - 2023/12
Y1 - 2023/12
N2 - Intracerebral haemorrhage (ICH) is a dramatic condition caused by the rupture of a cerebral vessel and the entry of blood into the brain parenchyma. ICH is a major contributor to stroke-related mortality and dependency: only half of patients survive for 1 year after ICH, and patients who survive have sequelae that affect their quality of life. The incidence of ICH has increased in the past few decades with shifts in the underlying vessel disease over time as vascular prevention has improved and use of antithrombotic agents has increased. The pathophysiology of ICH is complex and encompasses mechanical mass effect, haematoma expansion and secondary injury. Identifying the causes of ICH and predicting the vital and functional outcome of patients and their long-term vascular risk have improved in the past decade; however, no specific treatment is available for ICH. ICH remains a medical emergency, with prevention of haematoma expansion as the key therapeutic target. After discharge, secondary prevention and management of vascular risk factors in patients remains challenging and is based on an individual benefit–risk balance evaluation.
AB - Intracerebral haemorrhage (ICH) is a dramatic condition caused by the rupture of a cerebral vessel and the entry of blood into the brain parenchyma. ICH is a major contributor to stroke-related mortality and dependency: only half of patients survive for 1 year after ICH, and patients who survive have sequelae that affect their quality of life. The incidence of ICH has increased in the past few decades with shifts in the underlying vessel disease over time as vascular prevention has improved and use of antithrombotic agents has increased. The pathophysiology of ICH is complex and encompasses mechanical mass effect, haematoma expansion and secondary injury. Identifying the causes of ICH and predicting the vital and functional outcome of patients and their long-term vascular risk have improved in the past decade; however, no specific treatment is available for ICH. ICH remains a medical emergency, with prevention of haematoma expansion as the key therapeutic target. After discharge, secondary prevention and management of vascular risk factors in patients remains challenging and is based on an individual benefit–risk balance evaluation.
UR - http://www.scopus.com/inward/record.url?scp=85150665318&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150665318&partnerID=8YFLogxK
U2 - 10.1038/s41572-023-00424-7
DO - 10.1038/s41572-023-00424-7
M3 - Article
C2 - 36928219
AN - SCOPUS:85150665318
SN - 2056-676X
VL - 9
JO - Nature Reviews Disease Primers
JF - Nature Reviews Disease Primers
IS - 1
M1 - 14
ER -